UTHR
United Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About UTHR
United Therapeutics Corporation
A biotechnology company that develops and commercializes products to treat pulmonary arterial hypertension and other diseases
1000 Spring Street, Silver Spring, MD 20910
--
United Therapeutics Corporation was founded in Delaware in 1996. It is a biotechnology company dedicated to the development and commercialization of unique products that address the unmet medical needs of patients with chronic diseases and life-threatening conditions. Its revenue is mainly derived from the sales of Quqian Liannier, Tyvaso and Tadalafil. Their marketing and sales staff will try to make their products available in their authorized countries. These are mainly done by their professional distributors in the United States and other international distributors.
Earnings Call
Q1/2025
Estimate EPS6.28
Actual EPS6.63
Estimate Revenue726.36M
Actual Revenue794.40M
United Therapeutics Q1 2025: Key Contradictions on Tyvaso Sales, Patient Split, and Capital Strategy
May 07,2025 02:37
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS6.92
Actual EPS6.41
Estimate Revenue803.65M
Actual Revenue798.60M
United Therapeutics Q2 2025: Unpacking Contradictions in Tyvaso Growth, Share Buybacks, and Market Dynamics
Jul 30,2025 07:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
UTHR has released its 2025 Q3 earnings. EPS was reported at 7.16, versus the expected 6.96, beating expectations. The chart below visualizes how UTHR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
UTHR has released its 2025 Q3 earnings report, with revenue of 799.50M, reflecting a YoY change of 6.76%, and net profit of 338.70M, showing a YoY change of 9.58%. The Sankey diagram below clearly presents UTHR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
